Trials / Completed
CompletedNCT01439074
Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.
An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Molnlycke Health Care AB · Industry
- Sex
- All
- Age
- 5 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to compare time to healing using absorbent foam silver dressing (Mepilex Ag) compared to a silver sulfadiazine (SSD) 1% cream in the treatment of partial thickness burn injuries.284 in-patients in 8-12 centres in China will be evaluated. Treatment period will be up to 4 weeks with either Mepilex Ag or SSD.
Detailed description
Subjects enrolled in this investigation were in-patients at eleven centers in China. To be included, subjects had to have deep partial-thickness burn injuries. The subjects were consecutively allocated to a subject code providing they fulfilled all inclusion criteria and none of the exclusion criteria and had signed a written informed consent form. Two evaluators independent of each other made the judgment regarding depth of the burn before enrolling a subject. The subjects were randomized to either receive Mepilex Ag or SSD. Treatment period were up to four weeks with either SSD or Mepilex Ag. Changes of the investigation products were performed according to a standardized schedule, unless the wound healed before.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Mepilex Ag | Dressing |
| DRUG | Silver Sulphadiazine Ag cream | A cream used on burnt areas. |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2011-09-22
- Last updated
- 2017-12-18
- Results posted
- 2014-10-01
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01439074. Inclusion in this directory is not an endorsement.